Intracoronary Versus Intravenous Abciximab Bolus in Patients With ST-Segment Elevation Myocardial Infarction 1-Year Results of the Randomized AIDA STEMI Trial

In patients with ST-segment elevation myocardial infarction (STEMI), direct intracoronary as compared with standard intravenous bolus administration of the glycoprotein IIb/IIIa receptor antagonist abciximab acutely causes higher local drug concentrations, greater glycoprotein IIb/IIIa receptor occupancy, and enhanced inhibition of platelet aggregation at the site of thrombus and downstream within the coronary capillary bed (1). These effects might exert a protective effect on the myocardial microcirculation at the time of reperfusion.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - Category: Cardiology Source Type: research